New Survey: 84% of Respondents Would Participate in a Hospital-at-Home Program In Order To Get Home Sooner

Vivalink’s survey reveals strong consumer support for flexible care models, indicating a need for home based care as part of the national healthcare system

More than 300 Hospital at Home (HaH) programs have been approved across the country, allowing thousands of patients to be monitored in the comfort of their homes after leaving the hospital.

Vivalink, a leading provider of digital healthcare solutions, is sharing results from a new survey of more than 1,000 U.S. consumers 40 years and older about their opinions surrounding participating in a HaH program.

Key findings from the survey include:
  • An overwhelming 84% of respondents are willing to participate in HaH monitoring in order to return home sooner versus staying at the hospital to be monitored. 

  • 77% of respondents indicated that they would trust their healthcare provider’s recommendation to utilize HaH monitoring.

  • Of those who have experienced HaH, 84% reported having a positive experience with the program.

  • 49% of respondents who had participated in a HaH program found the remote patient monitoring (RPM) device easy to use. At the same time, of the 16% of respondents who were not likely to participate in HaH programs, difficulty with devices was cited as a top concern.
The survey also delved into demographic variations, uncovering insights based on age and location:
  • Older respondents (over 70) were less likely to have heard of HaH programs (42% vs. 77% of consumers in their 40s), or had participated in HaH programs (11% vs. 66%).

  • Urban participants were more likely to have participated in HaH programs (71% vs. 25% of rural respondents) but were less likely to prefer completely remote primary care compared to rural participants (19% vs. 36% of rural respondents). 

  • Respondents with three or more hospitalizations in the last 12 months demonstrated a higher willingness to participate in HaH programs (95% vs. 62% of respondents with 2 or fewer hospitalizations) and expressed greater trust in providers’ recommendations for HaH monitoring (95% vs 78%).
The survey’s findings are particularly compelling as the waivers introduced by the Centers for Medicare and Medicaid Services (CMS) in response to the COVID-19 pandemic, which allowed inpatient-level hospital services to be conducted in patients’ homes, are set to expire at the end of this year, emphasizing the need for permanent adoption of flexible care models like HaH programs.

“Consumers are increasingly driving the trend towards receiving care in the comfort of their own homes. This shift, accelerated by the COVID pandemic, underscores the importance of providing flexible and convenient healthcare solutions that meet patients’ evolving needs,” said Jiang Li, CEO of Vivalink. “At Vivalink, we are committed to the development of advanced digital healthcare solutions in order to improve access and efficiency of the healthcare system for all.”

For more details and infographics, click here.

SourceVivalink

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”